Clinical Trial Search

Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants…

Primary: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period — -8.64; -22.16 percent change — p==0.061

Primary: Testing Uptake- The Number of Valid Responses That Confirmed COVID-19 Testing Was Completed by Households — .1603; .2552; .2484 Valid response to message on testing

Primary: Treatment-emergent Adverse Events (TEAEs) — 115; 119 Participants

Primary: Percentage of Patients Who Achieved Clinical Response — 57; 35 percentage of patients — p=0.05

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 162; 44 Participants

Primary: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) — 9.0; 38.0 percentage of…

Primary: Number of Participants With and Without Virological Suppression — 84; 40; 3; 1 Participants

Primary: Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29 — 5.9; 6.0 days — p=0.0681

Primary: Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores. — -1.8; -1.2 score on a scale

Primary: Treatment-emergent Adverse Events (TEAEs) — 238 Participants

Primary: Change From Baseline of Mean Latency to Persistent Sleep (LPS) Over the Last 2 Nights of 1 Month of Treatment of Lemborexant 10 mg Compared to Placebo — -21.71; -39.47…

Primary: Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline — 6.07 score on a scale

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 866; 42 Participants

Primary: Number of Case Management Sessions Completed — 9.39; 7.69; 8.46 number of sessions